Posts

A rising tide scenario: Why other Big Pharmas could follow Lilly into psychedelics

on

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

on

Compass Pathways Hypes Durability of Psilocybin for Depression Ahead of Year‑End FDA Filing

on

Magnetic Seizure Therapy Shows Efficacy and Safety Comparable to Electroconvulsive Therapy for Depression

on

Compass Pathways Stock Soars on Second Phase 3 Success for Psilocybin Depression Treatment

on

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

on

A New Dawn for Psychedelics: Compass Pathways Nears Major Phase 3 Psilocybin Results

on

Supernus Pharmaceuticals' Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial

on

Supernus Pharmaceuticals' Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint

on

GH Research Reports Positive Phase 2b Results for Inhaled 5-MeO-DMT in Treatment-Resistant Depression

on